On February 10, 2021 Kezar Life Sciences, Inc. (Nasdaq:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, reported its Chief Executive Officer, John Fowler, will present a corporate overview at the BIO CEO & Investor Digital Conference, being held from February 16 – 18, 2021 (Press release, Kezar Life Sciences, FEB 10, 2021, View Source [SID1234574871]). Kezar’s Chief Scientific Officer, Chris Kirk, Ph.D., will participate in a panel discussion, "Progress in Drugging the Undruggable Cancer Targets" at the conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be available on demand on Tuesday, February 16, 2021 and may be accessed at the "Events & Presentations" section of the Company’s website at View Source Kezar Life Sciences will maintain an archived replay of the webcast on its website for 90 days after the conference.